Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

3508 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-14

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies. Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs (adverse events) leading to withdrawal.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

HIV Human Immunodeficiency Virus CAB LA Cabotegravir Apretude PrEP HPTN 083 HPTN 084 DAIDS

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CAB LA 600 mg (Q8W)

All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection.

Group Type EXPERIMENTAL

CAB LA

Intervention Type DRUG

Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAB LA

Participants will receive CAB LA 600 mg via gluteal IM injection, once every 8 weeks (Q8W).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Apretude CAB LA for PrEP

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Type of participant

1. Participants must have recently completed or be currently enrolled and ongoing in one of the following studies on the CAB LA arm:

* HPTN 083 open label extension
* HPTN 084 open label extension (including pregnancy sub-study)

Participants that completed study participation ≥3 months ago must be discussed with the Medical Monitor prior to enrolment.

Participants who have prematurely withdrawn from prior CAB PrEP studies cannot enroll into this study.
2. Evidence of continued benefit (HIV negative and at risk) from CAB LA during participation in the parent study/sub-study.
3. Participants must have nonreactive HIV tests at Screening (rapid test, immunoassay \[antigen/antibody\] test and HIV-1 RNA results must all be available and nonreactive) and Day 1 (at least one of rapid test and immunoassay \[antigen/antibody test\] results must be available and nonreactive). Participants who have one or more reactive or positive HIV test result(s) will not be enrolled, even if subsequent confirmatory testing indicates they are not HIV-infected.

Sex
4. Males and Females:

All participants who are engaging in sexual activity should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of acquiring HIV and other STIs.

Females:

Cisgender female participants who are of childbearing potential and who are engaging in sexual activity that could lead to pregnancy, must talk to the investigator about recommended contraception options. Contraception will be optional in this study. Condoms are recommended in addition, because their appropriate use is the only contraception method effective for preventing HIV-1 transmission.

Pregnant participants from the HPTN 084 study are eligible to enroll into this study if they meet all eligibility criteria.

Informed consent
5. Participant or caregiver/legal guardian is able and willing to provide signed informed consent as described in Protocol Section 11.1.5, which includes compliance with the requirements and restrictions listed in the consent form and in this protocol. Where applicable, participants must provide written assent.

8. Presence of or any history of allergy/sensitivity to the study drug or its components.
9. Inflammatory skin conditions that compromise the safety of IM injections, per the discretion of the investigator. Mild skin conditions may not be exclusionary at the discretion of the investigator or designee.
10. Participant has a gluteal implant, tattoo or other dermatological condition overlying the buttock region which in the opinion of the investigator or designee may interfere with the injection or interpretation of ISRs.
11. Coagulopathy (primary or iatrogenic) which would contraindicate IM injection. Concomitant medications
12. Participant is receiving any protocol-defined prohibited medication and is unwilling or unable to switch to an alternate medication.
13. Anticipated need for HCV therapy with interferon or any drugs that have potential for adverse drug: drug interactions with study treatment throughout the entire study period.

Relevant habits
14. Participant is unlikely to adhere to the study procedures, keep appointments, or is planning to relocate during the study.
15. Any condition (i(including but not limited to substance use disorder) that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol.

Other
16. Participant has in the last 14 days prior to screening presented with signs and symptoms, which, in the opinion of the investigator, are suggestive of acute HIV infection. Participants may only be enrolled if clinical suspicion of HIV is ruled out with non-reactive results using appropriate HIV tests as per Inclusion Criterion #3.
17. Participant is a ward of the state (e.g. child in care).

Exclusion Criteria

Concurrent conditions/medical history (includes liver function)

1. Participants who are currently enrolled in the eligible studies on the TDF/FTC arm are not eligible to enroll into this study. Participants receiving short-term oral TDF/FTC bridging may be enrolled following consultation with the Medical Monitor.
2. Previous premature discontinuation from IP in the parent study/sub-study.
3. ALT \>5 × ULN; or ALT\>3 × ULN and bilirubin \>1.5 × ULN (with \>35% direct bilirubin) in the screening liver chemistry test result.
4. Participants with known active hepatitis B infection (as indicated by a positive HBsAg and/or quantifiable HBV DNA). Participants negative for HBsAg but positive for anti-HBc and positive for anti-HBs (past and/or current evidence) are immune to HBV and are not excluded.
5. Unstable liver disease (as defined by any of the following: presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of hyperbilirubinemia or jaundice due to Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator).
6. Known history of cirrhosis with or without viral hepatitis co-infection.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Reach out to these primary contacts for questions about participation or study logistics.

US GSK Clinical Trials Call Center

Role: CONTACT

Phone: 877-379-3718

Review additional registry numbers or institutional identifiers associated with this trial.

221163

Identifier Type: -

Identifier Source: org_study_id

Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus)

Study Results

Basic Information

Brief Summary

Detailed Description

Conditions

Keywords

Study Design

Study Groups

CAB LA 600 mg (Q8W)

CAB LA

Interventions

CAB LA

Other Intervention Names

Eligibility Criteria

Inclusion Criteria

Exclusion Criteria

Sponsors

GlaxoSmithKline

PPD Development, LP

ViiV Healthcare

Responsible Party

Locations

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

GSK Investigational Site

Countries

Central Contacts

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Center

Facility Contacts

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre

US GSK Clinical Trials Call Center

EU GSK Clinical Trials Call Centre